Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × von Hippel-Lindau Disease × palbociclib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 21 Neoplasm Metastasis 8 Neoplasms by Site 2 Neoplasms 2 Breast Diseases 2 von Hippel-Lindau Disease 1 Unilateral Breast Neoplasms 1 Skin Diseases 1 Sarcoma 1 Recurrence 1 HER2+ Breast Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Carcinoma, Renal Cell 1 Breast Cancer Recurrent 1

Interventions

palbociclib 1 lenvatinib 1 cabozantinib 1 belzutifan 1 Nivolumab 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07405164 2026-02-12

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡